Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium breve is a probiotic bacterium that has been studied for its potential to treat or prevent diarrhea, particularly in children. Clinical trials and meta-analyses have shown that certain strains of B. breve can reduce the duration and severity of acute infectious diarrhea, especially when used in combination with other probiotic strains such as Lactobacillus and Streptococcus species. One randomized controlled trial in children demonstrated that a mixture containing B. breve reduced the duration of rotavirus-associated diarrhea. Another study indicated that B. breve may be beneficial in preventing antibiotic-associated diarrhea by helping to restore and maintain the balance of the gut microbiota during antibiotic therapy.

Despite these promising results, the quality and quantity of evidence are moderate. Many studies are small in scale, and there is variability in the strains used, dosages, and patient populations. Systematic reviews suggest a modest benefit but emphasize that more high-quality, large-scale studies are needed to confirm efficacy and determine optimal dosing regimens. The mechanism by which B. breve exerts its effects is thought to involve enhancement of the gut barrier, modulation of immune responses, and competitive inhibition of pathogenic microbes.

In summary, there is scientific evidence to support the use of Bifidobacterium breve for certain types of diarrhea, particularly in children, but the strength of this evidence is moderate (3/5) and should be interpreted with caution until larger trials are conducted.

More about bifidobacterium breve
More about Diarrhea

Other ingredients used for Diarrhea

Other health conditions supported by bifidobacterium breve

Products containing bifidobacterium breve